autologous blood and marrow transplantation - Blog Science ...

Kvalheim et al. 251
Figure 1. Sixty stage II high-risk breast cancer patients treated with high-dose therapy
PBPC support were examined by immunocytochemistry employing anticytokeratin mA
2310 6
bone marrow mononuclear cells and peripheral blood before treatment and in PB
were examined from each patient. Only CK +
cells with epithelial cell-like morphology w
scored as positive. BM, number positive in bone marrow at diagnosis; PB, number posi
in blood at diagnosis; PBPC, number positive in peripheral blood progenitor cell produc
therapy. Four patients became positive in the PBPC products without any known
micrometastases in bone marrow. Of those four, one had a positive marrow after
high-dose therapy. Four patients previously negative in both bone marrow and
PBPC became positive in the marrow after high-dose therapy. Among the patients
P re-treatment PBPC Post-treatment
• BMPre+PBPC+BMPost
SPBPC + BMPosl
BBMPost
Figure 2. Thirty-six stage II high-risk breast cancer patients treated with high-dose th
py with PBPC support were examined by immunocytochemistry employing anticytoke
mAbs. 2310 6
bone marrow mononuclear cells before treatment, in PBPC product and in
marrow 12 months after therapy were tested from each patient. Only CK +
cells with ep
cell-like morphology were scored as positive. Pre-treat+PBPC+post treat column, num
positive at all stages; PBPC+post-treat column, number that became positive in the PBPC
uct and after therapy; Post-treat column, number that became positive after therapy.